Prasugrel Hydrochloride - CAS 389574-19-0
Catalog number: 389574-19-0
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C20H21ClFNO3S
Molecular Weight:
409.9
COA:
Inquire
Targets:
P2Y Receptor
Description:
Prasugrel is a platelet inhibitor (IC50=1.8 μM) , as a third-generation thienopyridine.
Purity:
≥98%
Appearance:
Pale Beige Solid
Synonyms:
[5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] acetate;hydrochloride
Solubility:
Soluble in DMSO
Storage:
Store at 2-8 °C
MSDS:
Inquire
Application:
Antiplatelets; Antithrombotics
Quality Standard:
Enterprise Standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Quantity:
Grams-Kilos
Melting Point:
>118 °C
InChIKey:
JALHGCPDPSNJNY-UHFFFAOYSA-N
InChI:
1S/C20H20FNO3S.ClH/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21;/h2-5,10,13,19H,6-9,11H2,1H3;1H
Canonical SMILES:
CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4.Cl
Current Developer:
Daiichi Sankyo Company; Eli Lilly; Ube Industries
1.Stability-Indicating LC Method for the Determination of Prasugrel Hydrochloride in Pharmaceutical Dosage Form.
Ahirrao VK;Patil CS;Bembalkar SB;Ubale SB;Marathe RP;Nawale RB;Landge MG;Pawar RP Sci Pharm. 2012 Apr-Jun;80(2):379-91. doi: 10.3797/scipharm.1201-05. Epub 2012 Mar 20.
A simple, rapid and precise method was developed for the quantitative estimation of prasugrel hydrochloride in pharmaceutical dosage form. A chromatographic separation of prasugrel and its degradants was achieved with Zorbax XDB C(8), 150 × 4.6 mm, 3.5μm analytical column using aqueous solution of 0.05 M ammonium acetate pH 4.5 with acetic acid-acetonitrile (40:60 v/v). The instrumental settings include flow rate of 1.0 ml/min, column temperature at 30°C and detector wavelength of 254 nm using a photodiode array detector. Theoretical plates for prasugrel were 7023. Tailing factor for prasugrel was 1.11. Prasugrel was exposed to thermal, photolytic, hydrolytic and oxidative stress conditions, and the stressed samples were analyzed by the proposed method. Peak homogeneity data of prasugrel was obtained using photodiode array detector in the stressed sample chromatograms, which demonstrated the specificity of the method for the estimation in presence of degradants. The described method showed excellent linearity over a range of 10-300 μg/ml for prasugrel. The correlation coefficient is 0.999. The relative standard deviation of peak area for six measurements is always less than 2%. Overall, the proposed method was found to be suitable and accurate for quantitative determination and stability study of prasugrel in pharmaceutical dosage form.
2.Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016.
Dayoub EJ;Seigerman M;Tuteja S;Kobayashi T;Kolansky DM;Giri J;Groeneveld PW JAMA Intern Med. 2018 Jul 1;178(7):943-950. doi: 10.1001/jamainternmed.2018.0783.
Importance: ;Current guidelines recommend prasugrel hydrochloride and ticagrelor hydrochloride as preferred therapies for patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI). However, it is not well known how frequently these newer agents are being used in clinical practice or how adherence varies among the platelet adenosine diphosphate P2Y12 receptor (P2Y12) inhibitors.;Objectives: ;To determine trends in use of the different P2Y12 inhibitors in patients who underwent PCI from 2008 to 2016 in a large cohort of commercially insured patients and differences in patient adherence and costs among the P2Y12 inhibitors.;Design, Setting, and Participants: ;A retrospective cohort study used administrative claims from a large US national insurer (ie, UnitedHealthcare) from January 1, 2008, to December 1, 2016, comprising patients aged 18 to 64 years hospitalized for PCI who had not received a P2Y12 inhibitor for 90 days preceding PCI. The P2Y12 inhibitor filled within 30 days of discharge was identified from pharmacy claims.;Main Outcomes and Measures: ;Proportion of patients filling prescriptions for P2Y12 inhibitors within 30 days of discharge by year, as well as medication possession ratios (MPRs) and total P2Y12 inhibitor copayments at 6 and 12 months for patients who received drug-eluting stents.
3.Prasugrel hydrochloride for the treatment of acute coronary syndrome patients.
Gunarathne A;Hussain S;Gershlick AH Expert Rev Cardiovasc Ther. 2016 Nov;14(11):1215-1226. doi: 10.1080/14779072.2016.1245145.
Dual antiplatelet therapy (DAPT) with aspirin combined with either a thienopyridine (clopidogrel or prasugrel) or acyclopentyl-triazolo-pyrimidine (ticagrelor) plays a vital role in the management of acute coronary syndrome (ACS) especially in those undergoing percutaneous coronary intervention (PCI) but even those being managed medically. Observational studies and some formal studies have shown patients on the standard dual antiplatelet regimen (clopidogrel and aspirin) continue to have further ischemic events and can suffer stent thrombosis. It has been demonstrated that clopidogrel is associated with a delayed onset of action with a considerable inter-individual variation to treatment thus making it difficult to achieve an optimal level of platelet inhibition. Areas covered: This article will review the current evidence that is available regarding the effectiveness and safety of prasugrel in ACS patients undergoing percutaneous coronary intervention (PCI). Expert commentary: Prasugrel is an oral third-generation inhibitor of platelet activation and aggregation. Laboratory studies and early phase clinical trials show prasugrel has a faster onset of action, is more potent and has reduced inter-patient response variability compared to clopidogrel.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related P2Y Receptor Products


CAS 274693-27-5 Ticagrelor

Ticagrelor
(CAS: 274693-27-5)

Ticagrelor, the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Used in...

CAS 1006028-37-0 NF 546

NF 546
(CAS: 1006028-37-0)

NF 546 is a P2Y11 agonist with pEC50 value of 6.27. It can stimulate release of interleukin-8 from human monocyte-derived dendritic cells.

Regrelor
(CAS: 787548-03-2)

Regrelor is a P2Y12 antagonist. In Dec 2008, Phase-II for Thrombosis in USA was discontinued.

CAS 1343364-54-4 αβ-methylene ATP

αβ-methylene ATP
(CAS: 1343364-54-4)

αβ-methylene ATP, a phosphonic analog of ATP, is an agonist of P2X purinoceptors P2X1 and P2X3 (EC50 = ~1 µM) and is ~1,000-fold less potent at P2X2, P2X recept...

CAS 711019-86-2 MRS 2578

MRS 2578
(CAS: 711019-86-2)

MRS2578 is a potent P2Y6 receptor antagonist with IC50 of 37 nM, exhibits insignificant activity at P2Y1, P2Y2, P2Y4,and P2Y11 receptors.

CAS 120202-66-6 Clopidogrel

Clopidogrel
(CAS: 120202-66-6)

Clopidogrel is converted to its active metabolite by cytochrome P450 (CYP) enzymes.

CAS 202982-98-7 NF 340

NF 340
(CAS: 202982-98-7)

NF 340 is a selective P2Y11 antagonist. It shows competitive antagonism against ATPγS with pIC50 values of 6.43 and 7.14 in Ca2+ and cAMP assays respectively.

CAS 145782-74-7 AR-C 66096 tetrasodium salt

AR-C 66096 tetrasodium salt
(CAS: 145782-74-7)

The sodium salt form of AR-C 66096, which has been found to be a P2Y12 receptor antagonist and could be probably used as an antithrombotic agent.

Chemical Structure

CAS 389574-19-0 Prasugrel Hydrochloride

Quick Inquiry

Verification code

Featured Items